Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis ...

Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to its shareholders on 30 March, outlining the Company's strategic direction, accomplishments, and future plans.

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.